ACTINIC KERATOSIS PDT
TREATING FIELD CANCERISATION OF SUN-DAMAGED SKIN
Actinic keratoses are not isolated spots โ they are the visible tip of a field of sun-damaged skin that contains many subclinical lesions waiting to appear. PDT treats the whole field simultaneously, addressing visible AKs and the surrounding damaged skin in a single session.
analyticsAt a Glance
- check_circleTreats the entire sun-damaged field, not just visible lesions โ prevents new AKs from emerging
- check_circleALA or MAL cream applied for 3 hours; red LED lamp activates for 8 minutes
- check_circleTwo sessions 1 week apart; 70โ90% clearance at 3 months
- check_circleDaylight PDT: 2 hours outdoors with sunscreen โ equivalent efficacy, substantially less discomfort
What Is Field Cancerisation โ and Why It Changes How We Treat AK
The concept of "field cancerisation" explains why PDT is fundamentally better suited to actinic keratosis than cryotherapy. The field concept changes the treatment goal from "treating spots" to "treating an area of at-risk skin."
โTreating actinic keratoses with cryotherapy one-by-one is like pulling weeds individually while leaving the seeds in the soil. PDT treats the whole field โ visible AKs and the invisible damage around them.โ
The Field Cancerisation Model
Chronic UV exposure drives genetic mutations across an entire anatomical field โ the whole face, the entire scalp, the forearm surface โ not just where individual AKs are visible. The visible scaly lesions are simply the areas where clonal expansion has progressed far enough to be apparent. The surrounding "normal-looking" skin contains numerous subclinical dysplastic cells that will become new AKs over time.
Why Spot Treatment Is Inadequate
Cryotherapy freezes individual visible AKs โ but leaves the subclinical field untreated. New AKs emerge from the same field within months, requiring repeated visits and treatments. Studies consistently show patients treated with field therapy (PDT, topical 5-FU, imiquimod) for several years have lower rates of squamous cell carcinoma development compared to patients managed with spot treatments only.
Why PDT Is the Preferred Field Treatment for AK
PDT offers a unique combination of advantages for AK field treatment that no other option matches: high clearance rates, cosmetically excellent outcomes, ability to treat large areas in a single session, and the daylight PDT option.
Treats Visible and Subclinical Lesions Simultaneously
ALA and MAL cream is applied to the entire field (e.g., the whole face, entire bald scalp, or full forearm surface). The photosensitiser is activated in all dysplastic cells throughout the treated area โ not just the visible AKs. This simultaneously clears existing lesions and reduces the subclinical burden.
Outstanding Cosmetic Outcomes
PDT does not scar โ it causes inflammation and selective death of dysplastic cells, with normal skin healing cleanly. Many patients notice cosmetic improvement (reduced redness, improved texture, lightened pigmentation) in the treated field beyond just AK clearance. This is particularly valued on the face.
Large Area Treatment in One Session
A single PDT session treats the entire affected field โ the whole face, a 10ร15 cm forearm area, or the full scalp. Equivalent cryotherapy coverage would require dozens of individual freeze-thaw cycles and multiple clinic visits.
Daylight PDT: Patient-Friendly Alternative
Daylight PDT (2 hours outdoor exposure after SPF30 sunscreen application and cream application) achieves equivalent AK clearance to conventional lamp PDT with substantially less pain โ a major patient-experience advantage. Available when outdoor light >10,000 lux is accessible.
AK Treatment Options Comparison
How PDT compares to other standard actinic keratosis treatments.
| Treatment | AK Clearance Rate | Field Treatment | Best For |
|---|---|---|---|
| PDT (ALA or MAL, 2 sessions) | 70โ90% at 3 months | Yes โ full field treated | Multiple/widespread AKs; field cancerisation; cosmetically sensitive areas |
| Daylight PDT (ALA/MAL) | 65โ85% at 3 months | Yes | Good for mild-moderate AK in appropriate climate; better-tolerated |
| Cryotherapy | 75โ90% per lesion | No โ spot treatment only | Few isolated thick AKs; quick treatment; low-volume disease |
| Topical 5-Fluorouracil (Efudix) | 70โ90% field clearance | Yes | Good field option; intense inflammatory reaction; patient compliance challenge |
| Imiquimod (Aldara) | 50โ75% field clearance | Yes | Field treatment; less inflammatory than 5-FU; slower response |
| Diclofenac (Solaraze) | 40โ60% at 90 days | Yes | Mild AK; well tolerated; longer treatment course |
| Tirbanibulin (Klisyri) | 44โ54% at day 57 | Yes โ 25 cmยฒ | Limited field size; good tolerability; newer agent |
Standard AK-PDT Protocol
The clinic protocol for conventional lamp-based ALA or MAL-PDT for actinic keratosis.
- 1
Step 1: Field Preparation
Any very thick hyperkeratotic AKs are gently curetted or debrided with emery paper to reduce the barrier to cream penetration. The treatment area is cleaned with saline or alcohol. The field boundary is marked (e.g., entire face, specific forearm segment, bald scalp).
- 2
Step 2: ALA or MAL Cream Application
Cream is applied 1 mm thick over the entire treatment field including 5 mm beyond visible AKs. Covered with an occlusive film dressing. Patient waits 3 hours (MAL standard) or up to 6 hours (some ALA protocols). For daylight PDT: no occlusion; patient proceeds outdoors after 30 min SPF30 application.
- 3
Step 3: Red LED Light Delivery
Occlusive dressing removed. Red LED panel (630 nm) delivers 37โ75 J/cmยฒ over 7โ8 minutes. Cooling air (cold air blower) directed at the treatment field during light delivery minimises discomfort. For daylight PDT: 2 hours outdoor light replaces this step.
- 4
Step 4: Post-Treatment Care
Treated area will be red, swollen, and may form mild crusting over the following week. Emollient cream applied 2โ3ร daily. Sun/bright light avoidance of treated area for 24โ48 hours. No occlusive dressings after treatment.
- 5
Step 5: Second Session (1 Week Later)
Standard AK-PDT protocols use 2 sessions 1 week apart. The second session treats residual AKs not cleared by the first, and further reduces subclinical dysplastic burden in the field. Clinical studies show substantially higher clearance rates with 2-session vs single-session protocols.
- 6
Step 6: Response Assessment (3 Months)
Clinical assessment at 3 months evaluates AK clearance rate. Persistent lesions identified and managed (additional PDT, cryotherapy, or biopsy for thick persistent lesions). Maintenance PDT every 6โ12 months may be recommended for high-risk patients with persistent field change.
Explore the PDT Knowledge Base
Related PDT topics and resources.
- ALA and Methyl-ALA: Topical Photosensitisers for Skin Cancer PDT
- Basal Cell Carcinoma PDT: A Non-Surgical Option for Facial BCC
- PDT Photosensitivity: The Complete Protection Guide
- What Is Photodynamic Therapy and How Does It Work?
- Skin Cancer โ Condition Page
- Photodynamic Therapy โ Full Treatment Page
Frequently Asked Questions
Common questions about PDT for actinic keratosis.
About the Treatment
How much does my face swell and crust after AK-PDT?
Post-treatment reaction varies considerably between patients and treatment areas. The face typically develops significant redness and swelling within hours that peaks at 24โ48 hours. Mild crusting forms over treated AKs during the first week. By 2 weeks, most patients look essentially normal with improved skin texture. The reaction on the forearms is typically milder; the lower legs can be more pronounced due to less vascularity. Cooling during light delivery and cold compresses post-treatment minimise severity.
Will I need multiple courses of PDT over the years?
For patients with significant field cancerisation, PDT is often repeated annually or every 1โ2 years. The treated field does not permanently eliminate the risk of new AKs โ sun damage is already present in the skin, and ongoing UV exposure (even with good sun protection) continues the field damage process. Many patients develop a relationship with their dermatologist for regular field treatment โ PDT, topical agents, or both โ as a skin cancer prevention programme.
Practical Questions
Is daylight PDT available everywhere?
Daylight PDT is available at dermatology centres offering ALA or MAL skin PDT in appropriate climates. It requires adequate outdoor light intensity (>10,000 lux), making it seasonal in northern climates โ most suitable in spring through autumn. In tropical and subtropical climates, daylight PDT is available year-round. Your treating dermatologist will advise whether daylight PDT is appropriate for your season and location.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Extensive Actinic Keratoses Across Your Face or Scalp?
PDT field treatment may be the most effective and cosmetically best option for managing your sun-damaged skin. Our team can identify specialist skin PDT centres and guide you on the most appropriate protocol.
For informational purposes only. AK treatment decisions require evaluation by a qualified dermatologist.